Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Notable Studies: Once-Weekly Semaglutide for Weight Management: A Clinical Review Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials Also Known As: Ozempic, Rybelsus, Wegovy, A10BJ06 Research Applications: Anti-obesity and weight loss Glycemic control Cardiovascular health Neuroprotection Risks: Gastrointestinal upset and related reactions Link to thyroid C-cell tumors in rodent studies Contraindicated in Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Risk of acute and chronic pancreatitis FDA approval only for T2D and overweight/obese subjects Chemical Structure What is Semaglutide
Management guided FY27 EBITDA margins of 25.5-26.5%, up from 25.4% in FY26, suggesting incremental margin expansion through operating leverage and BSV synergies
Yet, their potential reaches beyond these effects
Mller TD, Finan B, Bloom SR, DAlessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, et al
US$ 22.99
US$ 22.55
US$ 27.37
US$ 22.65
